Table 1 Mendelian randomization (MR) results for metabolites that were significantly associated with the risk of a particular cancer type using the inverse-variance weighted (IVW) approach
Metabolite ID | Annotation | Number of IVs | IVW | Weighted median | Egger regression | MR-PRESSO | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
OR (95% CI) | P | Pbonfer | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | |||
Breast cancer | |||||||||||
 M52468 | 1-Stearoyl-2-linoleoyl-GPI (18:0/18:2) | 30 | 0.93 (0.91–0.95) | 1.67 × 10−8 | 7.96 × 10−6 | 0.94 (0.90–0.98) | 7.46 × 10−3 | 0.92 (0.87–0.98) | 0.01 | 0.93 (0.91–0.95) | 1.33 × 10−6 |
 M53013 | Glycosyl-N-palmitoyl-sphingosine | 21 | 0.93 (0.90–0.96) | 2.61 × 10−6 | 1.24 × 10−3 | 0.96 (0.91–1.00) | 0.06 | 0.97 (0.91–1.04) | 0.45 | 0.93 (0.90–0.96) | 1.38 × 10−4 |
 M46799 | 1-Oleoyl-3-linoleoyl-glycerol (18:1/18:2) | 20 | 0.92 (0.89–0.95) | 1.42 × 10−6 | 6.78 × 10−4 | 0.90 (0.83–0.97) | 0.02 | 0.94 (0.82–1.07) | 0.33 | 0.92 (0.89–0.95) | 3.26 × 10−5 |
 M36594 | 1-Linoleoyl-GPI (18:2)* | 9 | 0.91 (0.87–0.95) | 1.63 × 10−5 | 7.75 × 10−3 | 0.89 (0.83–0.95) | 0.01 | 0.92 (0.78–1.09) | 0.38 | 0.91 (0.87–0.95) | 2.58 × 10−3 |
 M42574 | Glycohyocholate | 8 | 0.91 (0.87–0.95) | 5.72 × 10−5 | 0.03 | 0.94 (0.87–1.02) | 0.21 | 0.96 (0.83–1.11) | 0.60 | 0.91 (0.88–0.94) | 1.19 × 10−3 |
 M20699 | Erythritol | 6 | 0.89 (0.85–0.94) | 1.32 × 10−5 | 6.31 × 10−3 | 0.91 (0.84–0.97) | 0.04 | 0.93 (0.85–1.02) | 0.18 | 0.89 (0.86–0.94) | 4.60 × 10−3 |
 M31787 | 3-Carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF) | 5 | 1.24 (1.12–1.39) | 8.84 × 10−5 | 0.04 | 1.33 (1.10–1.60) | 0.04 | 1.15 (0.69–1.94) | 0.63 | 1.24 (1.12–1.39) | 0.02 |
 M33009 | Homostachydrine* | 4 | 0.84 (0.78–0.90) | 4.37 × 10−7 | 2.09 × 10−4 | 0.85 (0.78–0.94) | 0.04 | 0.95 (0.71–1.28) | 0.79 | 0.84 (0.80–0.87) | 3.21 × 10−3 |
 M34399 | 3,7-Dimethylurate | 4 | 0.82 (0.75–0.89) | 7.89 × 10−7 | 3.77 × 10−4 | 0.79 (0.70–0.89) | 0.03 | 0.99 (0.62–1.57) | 0.96 | 0.82 (0.76–0.88) | 0.01 |
 M52865 | X-24544 | 26 | 0.95 (0.93–0.97) | 5.62 × 10−5 | 0.03 | 0.95 (0.91–1.00) | 0.05 | 1.00 (0.94–1.06) | 0.97 | 0.95 (0.93–0.97) | 1.14 × 10−4 |
 M46398 | X-21353 | 7 | 0.90 (0.86–0.95) | 9.53 × 10−5 | 0.04 | 0.91 (0.86–0.97) | 0.03 | 0.91 (0.80–1.03) | 0.20 | 0.90 (0.87–0.94) | 2.56 × 10−3 |
Colorectal cancer | |||||||||||
 M33387 | 2-Arachidonoyl-GPC (20:4)* | 21 | 1.11 (1.08–1.13) | 4.13 × 10−15 | 2.07 × 10−12 | 1.11 (1.08–1.14) | 1.84 × 10−6 | 1.11 (1.05–1.16) | 5.55 × 10−4 | 1.11 (1.08–1.13) | 1.56 × 10−7 |
 M52713 | 1-(1-Enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1)* | 21 | 1.06 (1.03–1.09) | 7.60 × 10−5 | 0.04 | 1.08 (1.03–1.13) | 2.99 × 10−3 | 1.05 (0.99–1.12) | 0.12 | 1.06 (1.03–1.09) | 3.47 × 10−4 |
 M01110 | Arachidonate (20:4n6) | 20 | 1.13 (1.10–1.16) | 5.62 × 10−17 | 2.82 × 10−14 | 1.14 (1.10–1.19) | 1.18 × 10−6 | 1.15 (1.09–1.21) | 4.41 × 10−5 | 1.13 (1.10–1.16) | 1.03 × 10−8 |
 M52613 | 1-(1-Enyl-stearoyl)-2-arachidonoyl-GPC (P-18:0/20:4) | 20 | 1.13 (1.10–1.16) | 1.61 × 10−18 | 8.04 × 10−16 | 1.12 (1.08–1.16) | 2.98 × 10−6 | 1.13 (1.08–1.19) | 1.14 × 10−4 | 1.13 (1.10–1.16) | 6.35 × 10−9 |
 M00590 | Hypotaurine | 9 | 0.83 (0.78–0.90) | 5.84 × 10−7 | 2.93 × 10−4 | 0.86 (0.75–0.99) | 0.07 | 0.73 (0.58–0.93) | 0.03 | 0.83 (0.79–0.88) | 8.75 × 10−5 |
 M52673 | 1-(1-Enyl-palmitoyl)-2-arachidonoyl-GPE (P-16:0/20:4)* | 9 | 1.21 (1.14–1.30) | 3.92 × 10−9 | 1.97 × 10−6 | 1.25 (1.16–1.35) | 3.87 × 10−4 | 1.32 (1.16–1.49) | 3.71 × 10−3 | 1.21 (1.14–1.30) | 3.67 × 10−4 |
 M52715 | 1-(1-Enyl-palmitoyl)-2-myristoyl-GPC (P-16:0/14:0)* | 9 | 1.13 (1.07–1.19) | 2.35 × 10−5 | 0.01 | 1.12 (1.04–1.22) | 0.02 | 1.04 (0.90–1.21) | 0.59 | 1.13 (1.07–1.19) | 2.88 × 10−3 |
 M52738 | 1-Stearoyl-2-meadoyl-GPC (18:0/20:3n9)* | 9 | 1.16 (1.10–1.23) | 1.86 × 10−7 | 9.31 × 10−5 | 1.19 (1.13–1.25) | 1.88 × 10−4 | 1.21 (1.10–1.34) | 7.19 × 10−3 | 1.16 (1.10–1.23) | 8.09 × 10−4 |
 M38165 | Palmitoyl ethanolamide | 8 | 1.09 (1.05–1.14) | 6.08 × 10−5 | 0.03 | 1.10 (1.03–1.16) | 0.02 | 1.07 (0.95–1.22) | 0.32 | 1.09 (1.06–1.13) | 1.58 × 10−3 |
 M52474 | 1-(1-Enyl-palmitoyl)-GPC (P-16:0)* | 7 | 1.19 (1.10–1.29) | 2.22 × 10−5 | 0.01 | 1.22 (1.07–1.40) | 0.02 | 0.97 (0.71–1.32) | 0.85 | 1.19 (1.10–1.29) | 4.20 × 10−3 |
 M46701 | X-19141 | 70 | 0.95 (0.94–0.97) | 3.08 × 10−12 | 1.54 × 10−9 | 0.95 (0.93–0.97) | 1.14 × 10−6 | 0.96 (0.94–0.98) | 5.96 × 10−4 | 0.95 (0.94–0.96) | 5.08 × 10−12 |
 M46601 | X-11470 | 55 | 0.92 (0.90–0.95) | 2.30 × 10−10 | 1.15 × 10−7 | 0.92 (0.86–0.98) | 8.76 × 10−3 | 0.93 (0.87–1.00) | 0.06 | 0.92 (0.90–0.95) | 1.70 × 10−8 |
 M47651 | X-11491 | 45 | 0.96 (0.95–0.98) | 3.72 × 10−7 | 1.86 × 10−4 | 0.96 (0.94–0.98) | 4.13 × 10−5 | 0.95 (0.92–0.97) | 5.86 × 10−5 | 0.96 (0.95–0.98) | 5.19 × 10−6 |
 M47653 | X-11593 | 34 | 1.04 (1.02–1.06) | 1.50 × 10−5 | 7.49 × 10−3 | 1.03 (1.01–1.06) | 4.69 × 10−3 | 1.01 (0.98–1.04) | 0.48 | 1.04 (1.02–1.05) | 1.81 × 10−6 |
 M46515 | X-21470 | 24 | 1.06 (1.03–1.09) | 7.74 × 10−5 | 0.04 | 1.04 (1.00–1.08) | 0.05 | 1.03 (0.98–1.09) | 0.26 | 1.06 (1.03–1.09) | 6.33 × 10−4 |
 M46459 | X-01911 | 6 | 1.13 (1.06–1.20) | 9.52 × 10−5 | 0.05 | 1.12 (1.03–1.22) | 0.04 | 1.15 (0.97–1.37) | 0.19 | 1.13 (1.07–1.20) | 8.61 × 10−3 |
Lung cancer | |||||||||||
 M34407 | Isovalerylcarnitine | 21 | 0.83 (0.79–0.88) | 9.37 × 10−12 | 4.25 × 10−9 | 0.80 (0.73–0.88) | 1.09 × 10−4 | 0.80 (0.69–0.94) | 0.01 | 0.83 (0.80–0.87) | 5.25 × 10−8 |
 M35186 | 1-Arachidonoyl-GPE (20:4n6)* | 24 | 1.12 (1.07–1.17) | 1.32 × 10−6 | 5.97 × 10−4 | 1.10 (1.03–1.17) | 8.96 × 10−3 | 1.12 (1.02–1.22) | 0.03 | 1.12 (1.08–1.16) | 3.89 × 10−6 |
 M15716 | Imidazole lactate | 44 | 0.95 (0.92–0.97) | 7.22 × 10−5 | 0.03 | 0.96 (0.92–0.99) | 0.02 | 0.95 (0.90–1.00) | 0.05 | 0.95 (0.93–0.97) | 4.70 × 10−5 |
 M46410 | X-21365 | 25 | 0.90 (0.85–0.94) | 3.09 × 10−5 | 0.01 | 0.88 (0.81–0.96) | 7.63 × 10−3 | 0.90 (0.80–1.00) | 0.07 | 0.90 (0.85–0.94) | 2.45 × 10−4 |
Ovarian cancer | |||||||||||
 M34401 | 5-Acetylamino-6-formylamino-3-methyluracil | 41 | 1.07 (1.04–1.09) | 8.96 × 10−7 | 4.36 × 10−4 | 1.06 (1.03–1.10) | 1.77 × 10−3 | 1.05 (1.01–1.10) | 0.02 | 1.07 (1.04–1.09) | 6.19 × 10−6 |
 M34424 | 5-Acetylamino-6-amino-3-methyluracil | 28 | 1.10 (1.05–1.15) | 1.71 × 10−5 | 8.33 × 10−3 | 1.11 (1.05–1.18) | 9.77 × 10−4 | 1.12 (1.04–1.21) | 6.68 × 10−3 | 1.10 (1.05–1.15) | 1.53 × 10−4 |
 M01558 | 4-Acetamidobutanoate | 25 | 1.11 (1.06–1.16) | 2.20 × 10−5 | 0.01 | 1.12 (1.06–1.19) | 9.65 × 10−4 | 1.14 (1.05–1.24) | 5.08 × 10−3 | 1.11 (1.06–1.16) | 1.48 × 10−4 |
 M37496 | N-acetylputrescine | 25 | 1.10 (1.06–1.15) | 1.44 × 10−5 | 7.03 × 10−3 | 1.11 (1.05–1.18) | 1.93 × 10−3 | 1.13 (1.05–1.22) | 5.19 × 10−3 | 1.10 (1.06–1.15) | 2.87 × 10−5 |
 M34389 | 1-Methylxanthine | 22 | 0.91 (0.87–0.95) | 3.50 × 10−5 | 0.02 | 0.89 (0.83–0.95) | 1.70 × 10−3 | 0.86 (0.79–0.94) | 2.18 × 10−3 | 0.91 (0.87–0.95) | 1.90 × 10−4 |
 M44681 | Palmitoylcarnitine | 22 | 0.87 (0.82–0.93) | 4.14 × 10−5 | 0.02 | 0.86 (0.77–0.97) | 0.02 | 0.82 (0.69–0.97) | 0.03 | 0.87 (0.83–0.92) | 3.25 × 10−5 |
 M20458 | 1-Palmityl-GPC (O-16:0) | 5 | 0.70 (0.58–0.84) | 9.85 × 10−5 | 0.05 | 0.67 (0.51–0.90) | 0.05 | 0.86 (0.43–1.74) | 0.71 | 0.70 (0.65–0.74) | 4.01 × 10−4 |
Prostate cancer | |||||||||||
 M18368 | Cys-Gly, oxidized | 36 | 0.94 (0.91–0.96) | 5.51 × 10−6 | 2.71 × 10−3 | 0.92 (0.87–0.97) | 3.29 × 10−3 | 0.91 (0.85–0.98) | 0.01 | 0.94 (0.91–0.96) | 3.66 × 10−5 |
 M35136 | 5-Methyluridine (ribothymidine) | 31 | 1.05 (1.03–1.08) | 5.65 × 10−5 | 0.03 | 1.06 (1.02–1.10) | 4.71 × 10−3 | 1.06 (1.01–1.12) | 0.02 | 1.05 (1.03–1.07) | 4.63 × 10−6 |
 M33959 | N-acetyltryptophan | 24 | 0.92 (0.89–0.95) | 4.15 × 10−7 | 2.04 × 10−4 | 0.92 (0.87–0.98) | 0.01 | 0.94 (0.87–1.01) | 0.11 | 0.92 (0.89–0.95) | 2.30 × 10−5 |
 M19324 | 1-Stearoyl-GPI (18:0) | 5 | 0.78 (0.70–0.87) | 1.49 × 10−5 | 7.33 × 10−3 | 0.83 (0.68–1.01) | 0.13 | 0.54 (0.13–2.29) | 0.47 | 0.78 (0.70–0.87) | 0.01 |
 M48130 | N6-succinyladenosine | 4 | 1.21 (1.12–1.30) | 9.48 × 10−7 | 4.66 × 10−4 | 1.19 (1.09–1.31) | 0.03 | 1.22 (0.97–1.54) | 0.23 | 1.21 (1.12–1.30) | 0.02 |
 M46471 | X-12824 | 31 | 0.94 (0.91–0.97) | 3.60 × 10−5 | 0.02 | 0.94 (0.90–0.99) | 0.02 | 0.98 (0.92–1.04) | 0.43 | 0.94 (0.91–0.97) | 2.66 × 10−4 |
Renal cell cancer | |||||||||||
 M15681 | 4-Guanidinobutanoate | 22 | 1.14 (1.08–1.21) | 8.67 × 10−6 | 4.12 × 10−3 | 1.12 (1.04–1.22) | 8.39 × 10−3 | 1.14 (1.02–1.27) | 0.03 | 1.14 (1.08–1.20) | 8.59 × 10−5 |